Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: A randomized double-blind study

Clinical and Investigative Medicine

Volumn 25, Issue 6, 2002, Pages 243-251

  Halperin, Scott A ^a   McDonald, Jane ^b   Samson, Lindy ^c   Danzig, Lisa ^d   Santos, George ^d   Izu, Allen ^d   Smith, Bruce ^a   MacDonald, Noni ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC ANALGESIC AGENT; BACTERIUM ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS ACELLULAR PERTUSSIS INACTIVATED POLIOVIRUS HEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PENTACEL; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARM MUSCLE; ARTICLE; CANADA; CITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIARRHEA; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG USE; ERYTHEMA; FEVER; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA; INJECTION SITE; IRRITABILITY; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INDURATION; SOMNOLENCE; TETANUS; VOMITING;

ANTIBODY FORMATION; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOUBLE-BLIND METHOD; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MENINGOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 0036992772     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. National Advisory Committee on Immunization. Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001;27(ACS5,6):2-36.
2. Squires SG, Pelletier L, Mungai M, Tsang R, Collins F, Stoltz J. Invasive meningococcal disease in Canada, 1 January 1997 to 31 December 1998. Can Commun Dis Rep 2000;26:177-82.
3. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program, Streptococcus pneumoniae, 1998. Atlanta (Ga.): US Department of Health and Human Services, CDC; 1999. Available: www.cdc.gov/ncidod/dbmd/abcs/spneu98.pdf (accessed Nov. 14, 2002).
4. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program, Neisseria meningitidis 2000 (preliminary). Available: www.cdc.gov/ncidod/dbmd/abcs/survreports/mening00prelim.pdf (accessed Nov. 14, 2002).
5. Gold R, Lepow ML, Goldschneider I, Gotschlich EC. Immune response of human infants of polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977;136(Suppl):S31-5.
6. Reingold AL, Broome CV, Hightower AW, Ajello GW, Bolan GA, Adamsbaum C, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal poysaccharide vaccine. Lancet 1985;2:114-8.
7. King WJ, MacDonald NE, Wells G, Huong J, Allen U, Chan F, et al. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children. J Pediatr 1996;128:196-202.
8. Immunization Monitoring Program, Active (IMPACT). Recent trends in pediatric Haemophilus influenzae type b infections in Canada. CMAJ 1996;154: 1041-7.
9. Ramsay ME, Andrews N, Kaczmarski E, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001;357:195-6.
10. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunological memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers. JAMA 1998;280:1685-9.
11. Baker JD, Halperin SA, Edwards K, Miller B, Decker M, Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 1992;121:523-7.
12. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26.
13. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69:1568-73.
14. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. MMWR Recomm Rep 2000;49(RR-9):1-29.
15. Decker MD, Edwards KM. Combination vaccines: problems and promise. J Pediatr 2000;137:291-5.
16. Twumasi PA, Kumah S, Leach A, O'Dempsey TJ, Ceesay SJ, Todd J, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171:632-8.
17. Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000;19:144-50.
18. 197 in United States infants. Pediatr Infect Dis J 2001;20:153-9.
19. MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. JAMA 2000;283:2795-801.
20. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360-3.
21. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunological priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001;69:2378-82.
22. English M, MacLennan JM, Bowen-Morris JM, Deeks J, Boardman M, Brown K, et al. A randomised, double-blind, controlled trial of a meningococcal group C conjugate vaccine in young British infants. Vaccine 2001;19:1232-8.
23. Bramley JC, Hall T, Finn A, Buttery RB, Elliman D, Lockhart S, et al. Safety and irnmunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3, and 4 months of age. Vaccine 2001;19:2924-31.
24. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96(Suppl):S557-66.
25. Morris R, Halperin SA, Déry P, Mills E, Lebel M, MacDonald N, et al. IMPACT monitoring network: a better mousetrap. Can J Infect Dis 1993;4:194-5.
26. Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999;179:1569-72.
27. MacDonald NE, Halperin SA, Law BJ, Danzig LE, Granoff DM. Can meningococcal C conjugate vaccine overcome immune hyporesponsiveness induced by previous administration of plain polysaccharide vaccine? JAMA 2000;283:1826-7.